2-(2-Chloro-3-pyridinyl)-1H-1,3-benzimidazole

Catalog No. :
ACSNMA807
CAS No. :
143426-40-8
Molecular Formula :
C12H8ClN3
Molecular Weight :
229.67

IUPAC Name:2-(2-chloropyridin-3-yl)-1H-benzo[d]imidazole

2-(2-Chloro-3-pyridinyl)-1H-1,3-benzimidazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg95%$121.00Login to see priceInquiryInquiry
10mg95%$148.00Login to see priceInquiryInquiry
250mg95%$303.00Login to see priceInquiryInquiry
1g95%$554.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(2-Chloro-3-pyridinyl)-1H-1,3-benzimidazole
IUPAC Name2-(2-chloropyridin-3-yl)-1H-benzo[d]imidazole
MDL No.MFCD12025828
Molecular FormulaC12H8ClN3
Molecular Weight229.67
SMILESClC1(=NC=CC=C1C2(=NC3(=CC=CC=C3(N2))))
InChI KeyZCWQPSLCNFYEIH-UHFFFAOYSA-N
Synonym2-(2-Chloro-3-pyridinyl)-1H-1,3-benzimidazole;1H-Benzimidazole, 2-(2-chloro-3-pyridinyl)-;2-(2-Chloropyridin-3-yl)-1H-benzo[d]imidazole;2-(2-Chloropyridin-3-yl)-1H-1,3-benzodiazole
CAS No.143426-40-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACSNMA807 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSNMA807 route product structure diagram
    ACSNMA807143426-40-8
Inquiry

2. ACSNMA807 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNRTH015 route compound structure diagram
    ACNRTH01536404-88-3 In Stock
  4. Then
  5. ACSNMA807 route product structure diagram
    ACSNMA807143426-40-8
Inquiry

Comments (0)